Overactive bladder

GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases

Retrieved on: 
Wednesday, September 14, 2022
Autoimmunity, Therapy, Fever of unknown origin, CISC, Safety, Chemically induced dimerization, Knowledge, Inflammatory Bowel Diseases, NK, Patient, TCR, Overactive bladder, Technology, Immune tolerance, Benaroya Research Institute, The Promise, Interleukin, Degenerative disease, T1D, Conference, Bristol Myers Squibb, Multimedia, Seattle Children's, Immune system, Research institute, Vaccine, Pharmaceutical industry, Regulatory T cell, Hai-Genti, Regulatory T cell

CAMBRIDGE, Mass., Sept. 14, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced an upcoming presentation of preclinical data relating to the company's platform technology. The abstract, entitled "Finely Controlled IL-2 Signal in Engineered Human Tregs utilizing a Chemically Induced Signaling Complex (CISC)" will be presented at The Promise of IL-2 Conference in Paris, France on September 16, 2022.

Key Points: 
  • By way of background, Tregsare crucially important in addressing many diseases driven by uncontrolled autologous and allogeneic reactivity.
  • Further, interleukin-2 (IL-2) is the key cytokine for supporting Tregs homeostasis and its functional scarcity underpins many autoimmune diseases.
  • For Tregs therapeutics, IL-2 is essential to support in vivo Tregs stability, proliferation, and persistence, and hence, potency.
  • The company also has a collaboration with Bristol Myers Squibb for the development of Treg therapies for inflammatory bowel diseases.

Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

Retrieved on: 
Thursday, September 8, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Safety, Trial of the century, Medical school, Professor, Central European Time, Injection, Anatomy, Urinary urgency, CET, American Urological Association, Overactive bladder, Gesellschaft mit beschränkter Haftung, Patient, Female, Catheter, Urinary bladder, Department, Time in Europe, FDA, Beaumont Hospital, Abstract (summary), ICS, Beaumont, Cystoscopy, International Continence Society, Micturition syncope, NYSE, Urinary tract infection, Urination, Urinary incontinence, Science, Oakland University, Nocturia, OAB, BJU International, Urine, Pharmaceutical industry, Category, Urology, VideoRay UROVs

The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.

Key Points: 
  • The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.
  • The 2022 ICS Annual meeting is being held September 7-10, 2022, in a hybrid format with both online and in person participation (Vienna, Austria).
  • The podium presentation at ICS 2022 took place on Thursday, September 8, at 10:20 Central European Time (CET).
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System

Retrieved on: 
Thursday, September 8, 2022
Medical Devices, FDA, Hospitals, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Fecal incontinence, Incontinence, University of Alberta, University, INS, SNM, Department, Urinary incontinence, Health Canada, Deloitte Technology Fast 500, Quality of life, F15, Financial Times, Nasdaq, FDA, News, MRI, FRCS, U.S. FDA, Woman, SUI, Overactive bladder, Longevity, Adoption, Patient, Pharmaceutical industry, Medical device, Medical imaging, Axon reflex

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15, the companys newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15, the companys newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
  • The Axonics F15 received regulatory approval from Health Canada following U.S. FDA approval.
  • The approval of the Axonics recharge-free system is welcome news for patients in Canada suffering from bladder and bowel dysfunction, said Gary J.
  • Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.

Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)

Retrieved on: 
Wednesday, September 7, 2022
Clinical Trials, Human Resources, Biotechnology, Seniors, Other Science, Health, Research, Professional Services, Consumer, Publishing, Science, Nursing, Communications, Medical Supplies, Other Health, FDA, Practice Management, Physical Therapy, Managed Care, Pharmaceutical, Business, Medical Devices, Infectious Diseases, Hospitals, Fitness & Nutrition, People, Work, CEO, Man, Culture, Kopp, I, Upper respiratory tract infection, Organization, Urinary retention, Urinary urgency, Medicine, Urine, Overactive bladder, Twitter, Orange County Business Journal, Adult, Gesellschaft mit beschränkter Haftung, Nausea, Patient, Health, Sex, Great Places, Kidney, The Last Best Place, Vitamin, Headache, FDA, Nasal congestion, Diarrhea, Public health, Liver, LinkedIn, Multimedia, Instagram, Breast milk, 100 Best Workplaces in Europe, Sore throat, NYSE, Urinary tract infection, Vats, Achievement, Urinary incontinence, Urination, Allergy, Digoxin, Neurogenic bladder dysfunction, Nocturia, Burden, Feedback, Place, OAB, Health insurance, Management, Pharmaceutical industry, Risk management, Dietary supplement, Biopharma LLC, Sexton, Fortune, VideoRay UROVs

Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .

Key Points: 
  • Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .
  • Its an honor to be recognized by Fortune and Great Place to Work, said James Robinson, CEO of Urovant Sciences.
  • The Fortune Best Workplaces in BioPharma list is highly competitive.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo and Powered by People and Possibilities are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

NEUSPERA MEDICAL® APPOINTS STEFFEN HOVARD AS CEO

Retrieved on: 
Tuesday, September 6, 2022
CEO, Technology, Safety, II, SAN, SNM, Medtech, Physician, Quality of life, Conditional sentence, Overactive bladder, III, OAB, Growth, Health, Patient, Pharmaceutical industry, Medical device

SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ -- Neuspera® Medical, a medical device company developing implantable medical device technology for patients with chronic illness, today announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer. He joins as the company recently began enrollment of the second phase of its U.S. pivotal clinical trial (SANS-UUI). The study will evaluate the safety and efficacy of Neuspera's Nuvella™ system designed to treat patients with urinary urgency incontinence (UUI), which is a symptom of overactive bladder (OAB).

Key Points: 
  • SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ -- Neuspera Medical, a medical device company developing implantable medical device technology for patients with chronic illness, today announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer.
  • Steffen also serves as a board member for several companies in the medical device industry.
  • "I am excited to join Neuspera at this important time as the company builds momentum and clinical evidence for the Nuvella system," stated Steffen Hovard, CEO of Neuspera Medical.
  • Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses.

Cosmetic Surgery Global Market to Reach $48.84 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Surgery, Health, Muscle, American Society of Plastic Surgeons, Migraine, Plastic, Blemish (album), Society, Hyperhidrosis, Injection, Skin, Hospital, Beauty, Botulinum toxin, Overactive bladder, Growth, Dentistry

North America was the largest region in the cosmetic surgery market in 2021 and is expected to be the fastest-growing region in the forecast period.

Key Points: 
  • North America was the largest region in the cosmetic surgery market in 2021 and is expected to be the fastest-growing region in the forecast period.
  • The regions covered in the cosmetic surgery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
  • The rising number of cosmetic surgery hospitals is driving the growth of the cosmetic surgery market.
  • The increasing number of cosmetic surgery has raised the number of hospitals, free-standing ambulatory surgical facilities, and office premises to conduct cosmetic surgery procedures.

Colin P. Ryan, M.D., Joins Central Ohio Urology Group

Retrieved on: 
Monday, August 22, 2022
Oncology, Health, Hospitals, Surgery, Practice Management, Radiology, Incontinence, Georgetown University, Prostate cancer, Urinary tract infection, Science, Ohio State University College of Medicine, Urinary incontinence, Urination, Man, NMS, Pelvic organ prolapse, Radiation, Human science, Quality of life, Goal, University college, Urology, Urogynecology, Sexual dysfunction, Medicine, General surgery, Population, Female, Overactive bladder, Woman, Patient, Medical device, Dentistry

Corina Tracy, Chief Executive Officer of U.S. Urology Partners , the parent company of Central Ohio Urology Group , stated, We are pleased to welcome Dr. Colin Ryan to the care team at Central Ohio Urology Group.

Key Points: 
  • Corina Tracy, Chief Executive Officer of U.S. Urology Partners , the parent company of Central Ohio Urology Group , stated, We are pleased to welcome Dr. Colin Ryan to the care team at Central Ohio Urology Group.
  • Dr. Ryan said, I feel at home with the staff at Central Ohio Urology Group , who I know work hard to ensure the best care for patients.
  • To learn more about Dr. Colin P. Ryan or to schedule an appointment with the Central Ohio Urology Group care team , please visit www.centralohiourology.com or call (614) 396-2684.
  • Headquartered just outside of Columbus in Gahanna, Ohio, Central Ohio Urology Group provides comprehensive services , including general urology , mens health , womens health , cancer care , advanced cancer treatment and radiation oncology .

Axonics® to Participate in September Investor Conferences

Retrieved on: 
Thursday, August 18, 2022
General Health, Public Relations, Investor Relations, Medical Devices, Health, Communications, SUI, Woman, Financial Times, SNM, Overactive bladder, Nasdaq, Patient, Urinary incontinence, Deloitte Technology Fast 500, Fecal incontinence, Pharmaceutical industry, Dietary supplement, Axon Enterprise

1 on the 2021 Deloitte Technology Fast 500 and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Key Points: 
  • 1 on the 2021 Deloitte Technology Fast 500 and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.
  • Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.
  • In addition, the companys best-in-class urethral bulking hydrogel, Bulkamid, provides safe and durable symptom relief to women with stress urinary incontinence (SUI).
  • Axonics clinically proven products are offered at hundreds of medical centers across the U.S. and abroad.

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

Retrieved on: 
Wednesday, August 17, 2022
Mobile, Wireless, Technology, Medical Devices, Other Technology, Health Technology, Hardware, General Health, Pharmaceutical, Health, Consumer Electronics, Woman, Technology, Incontinence, Patent, United States Patent and Trademark Office, Fecal incontinence, SNM, Urinary incontinence, Lead, SUI, Financial Times, Overactive bladder, Nasdaq, Deloitte Technology Fast 500, Pharmaceutical industry, Dietary supplement, Axon Enterprise

Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence.

Key Points: 
  • Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence.
  • The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology, said Raymond W. Cohen, chief executive officer.
  • Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction.
  • Axonics sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.

Axonics® Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 1, 2022
Women, Seniors, Men, Health Technology, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Acquisition, Investment, Urinary incontinence, Awareness, Physician, SNM, U.S. Securities and Exchange Commission, Overactive bladder, Woman, Telephone, Solution, Private Securities Litigation Reform Act, Financial Times, Fecal incontinence, Webcast, Security (finance), Patient, Nasdaq, SUI, Deloitte Technology Fast 500, Pharmaceutical industry, Video game, Axon Enterprise

Net revenue was $69.0 million in second quarter 2022, an increase of 50% compared to $45.9 million in the prior year period.

Key Points: 
  • Net revenue was $69.0 million in second quarter 2022, an increase of 50% compared to $45.9 million in the prior year period.
  • Gross margin was 72.8% in second quarter 2022 compared to 62.6% in the prior year period.
  • Net loss was $21.4 million in second quarter 2022 compared to net loss of $25.1 million in the prior year period.
  • Axonics will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results and recent business developments.